A double-blind, randomized, phase II trial of the combination of adavosertib versus placebo plus standard platinum-based chemotherapy in patients with advanced, TP53-mutated platinum-sensitive ovarian cancer[78] failed to demonstrate a significant difference in objective response rate (74.6% vs. 69.4%, P = 0.52). Here, TP53 is linked to ovarian cancer.